
News|Articles|October 1, 2005
Pipeline Preview
Nelarabine (Arranon, GlaxoSmithKline) injection for the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in pediatric and adult patients whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens.
Advertisement
Recommendations for accelerated approval
Recommendations for approval
Orphan drug designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
2
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
3
Healthcare’s workforce has a scale problem, but new model is emerging
4
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
5


























